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Background/aims: Controversial results have been found in literature for the association
between  insulin resistance and sustained virologic response to standard chronic hepatitis C
treatment. This study aims to provide a systematic literature review with meta-analysis, in
order to evaluate if insulin resistance interferes with sustained virologic response in patients
infected by the HCV genotype 1 versus HCV genotypes 2 and 3, undergoing treatment with
interferon  and ribavirin or pegylated interferon and ribavarin.
Methods:  Systematic search was performed on main electronic databases until May 2012.
Primary  outcome was sustained virologic response, deﬁned as undetectable levels of HCV-
RNA  six months after the end of treatment. Meta-analytic measure was estimated using
Dersimonian  and Laird’s method, using Stata software.
Results: Thirteen studies involving 2238 infected patients were included. There was a sta-
tistically  signiﬁcant association between insulin resistance and lower sustained virologic
response  rate, and this difference occurred in HCV genotype G1 (OR: 2.23; 95% CI: 1.59–3.13)
and  G2/G3 (OR: 4.45; 95% CI: 1.59–12.49). In addition, a difference was seen in the cut-offs
used  for deﬁning insulin resistance by Homeostasis Model Assessment of Insulin Resistance.
To  minimize this limitation, sub-analysis that excluded the studies that did not use 2 as a
cut-off value was performed and the results still demonstrated association between insulin
resistance  and sustained virologic response, for both genotypic groups.
Conclusion:  This meta-analysis provides evidence that elevated Homeostasis Model Assess-ment  of Insulin Resistance is associated with a lower sustained virologic response rate in
patients  with hepatitis C treated with interferon and ribavirin or pegylated interferon and
ribavarin,  regardless of their genotype.
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Introduction
Chronic infection by the hepatitis C (HCV) virus is considered
to  be a major public health issue all over the world.1 Many
viral  and host factors have been implicated in disease pro-
gression  and/or response to antiviral treatment. Among those
factors  insulin resistance (IR) is noteworthy. Different stud-
ies  have demonstrated an association between HCV infection
and  increase in IR prevalence.2–6 IR is the main pathophysio-
logical mechanism of the metabolic syndrome, depending on
the tissue sensitivity to insulin.2,5 In hepatitis C IR is related
to  the presence of steatosis, faster ﬁbrosis progression and
increased  risk of progression to cirrhosis and hepatocellular
carcinoma.4,6–8
Molecular studies have demonstrated the capacity of hep-
atitis  C virus to promote IR by interfering with intracellular
insulin signaling, either by the virus itself or via an increase
in  the tumor necrosis factor (TNF-) production. This cytokine
or  viral core proteins can alter the residues of serine from the
insulin  substrate 1 and 2 receptors, as well as the expression
of  the cytokine suppressor substrate (SOCS). These changes
can  block the transactivation of glucose transporters (GLUT-4)
in  the cells, suppressing glucose uptake, leading to a hyper-
insulinism state.5,9–11 On the other hand, increasing SOCS-3
expression could reduce the response to treatment with inter-
feron  and ribavirin (IFN + RBV).11,12 In fact, many  studies
have demonstrated that the presence of IR, identiﬁed by the
HOMA-IR  index (Homeostasis Model Assessment of Insulin
Resistance)13,14 is associated with lower rates of sustained
virologic response (SVR) to treatment with pegylated inter-
feron  and ribavarin (PEG-IFN + RBV).15–19 Despite the evidence
shown in clinical and molecular studies, controversial results
have  been found in clinical practice regarding the association
between IR and response to the standard antiviral treatment
for  chronic hepatitis C.20–22
The recent introduction of protease inhibitors in the
treatment of genotype 1 carriers increases signiﬁcantly the
treatment  response rate, which does not seem to be inﬂuenced
by  IR.23,24 Nonetheless these drugs are not recommended to
non-1  genotypes and, also, in many  countries triple therapy
will  not be available to all patients and PEG-IFN + RBV will
remain  the standard treatment for many  subjects with chronic
hepatitis  C.
The  aim of the present study was  to provide a systematic
literature review with meta-analysis, in order to evaluate if the
IR  interferes with SVR in patients infected by the HCV geno-
type  1 (G1) versus HCV genotypes 2 and 3 (G2/G3), undergoing
treatment with IFN + RBV or PEG-IFN 2a or 2b + RBV.
Methods
Electronic search was  performed on the MEDLINE database
(via  PUBMED), Latin America and Caribbean Literature in
Health  Sciences (LILACS), EMBASE, Cochrane Central Register
of  Controlled Trials and The Cochrane Library until May 2012.
Electronic  search was  complemented by manual search from
bibliographic  references and abstracts from selected papers.
The  searches were  made using the words “genotype”, “hep-
atitis  C” and “insulin resistance” via controlled vocabulary 1 3;1  7(5):555–563
MeSH for the PUBMED database and adapted to the other
databases, according to their speciﬁcities. Language or time
limits  were not used.
The  following pre-deﬁned inclusion criteria were:  sys-
tematic  reviews, clinical trials, prospective or retrospective
observational studies, which reported the correlation between
HOMA-IR  and SVR, in subjects infected by the HCV (G1 or G2/3),
that  were  treatment naive, with 18 years old or above, from
any  ethnic group. The exclusion criteria were:  case reports;
studies  not carried out in humans; coinfection with human
immunodeﬁciency virus (HIV), and those with subjects under-
going  a therapy different from the ones deﬁned on this study
(PEG-IFN  + RBV or IFN + RBV).
The main outcome was  SVR, deﬁned by undetectable levels
of  HCV-RNA six months after the end of the treatment.
Two reviewers performed the search on the database using
the  strategies previously deﬁned and selected the trials to be
included in the review. Initially it was  agreed that in case a
consensus  was  not achieved, a third reviewer would be con-
sulted  regarding eligibility, and he would be responsible for
the  ﬁnal decision.
The  Stata software (11.2 version; Stata Corp., College
Station, TX, USA) was used for the statistical analysis. The
outcomes  were evaluated by dichotomous variables, for which
an  odds ratio (OR) and a 95% conﬁdence interval (CI) were
calculated. A p-value ≤ 0.05 was  considered statistically sig-
niﬁcant.  Initially the heterogeneity among the studies was
investigated with the Cochran’s Q test and I2 Higgins and
Thompson’s statistics, with equivalent signiﬁcances. Moder-
ate  heterogeneity was  identiﬁed for all the meta-analysis (I2
near 50% and less than 75%). Therefore, a random effects
model  was  considered and the meta-analytic measure (OR)
was  estimated using Dersimonian and Laird’s method, based
on  the assumption that there is heterogeneity among the stud-
ies.
Results
The systematic literature review performed in June 2012
resulted  in 84 bibliographic references from PUBMED, 4 bib-
liographic  references from LILACS and 247 bibliographic
references from EMBASE. After reading the titles and the
abstracts,  281 references that did not meet the eligibility crite-
ria  or were duplicated, were  excluded. Fifty-four papers were
selected  for more  detailed analysis of their contents. In addi-
tion,  papers from reference lists of the 54 selected papers
and  relevant paper reviews were added. At the end 13 studies
that  met  the inclusion criteria were considered in the meta-
analysis  (Fig. 1).
Characteristics  of  the  included  studies
The characteristics of the included studies are described in
Table  1. All the studies included are complete articles pub-
lished  in journals between 2005 and 2012. Most studies are
prospective,  observational, with only one being retrospec-
tive.  All included subjects were  treated with PEG-IFN 2a or
2b  + RBV, with duration depending on the viral genotype. For
IR  deﬁnition, the HOMA-IR index > 2 was considered, except
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Table 1 – Studies included in the meta-analysis.
Study Design  Viral
genotype
Number of patients Homa-IR cut off Mean homa-IR
(index ± SD)
SVR
association
Treatment
regimen
Akuta 200925 Observational
retrospective cohort
study
1  123 2.5 2.6 (2.6) No PEG-IFN 2b + RBV
Bortoletto 201021 Observational prospective
cohort  study
1  36 3 2.65  ± 2.01 Yes PEG-IFN  2b + RBV
2/3 21
Chu 200818 Observational
prospective cohort
study
1  133 2 2.93 (0.14) Yes PEG-IFN 2b + RBV
Conjeevaram 200729 Observational
prospective cohort
study
1  399 2 3.5 ± 5.0 Yes PEG-IFN 2a + RBV
Dai 200919 Observational prospective
cohort  study
1  150 2.5 2.24  (2.46) Yes PEG-IFN  2a/b + RBV
2/3 180 No
Eslam 201230 Observational prospective
cohort  study
1  64 2 3.02  ± 2.1 Yes PEG-IFN  2a/b + RBV
2 4
3  48
Fattovich 201020 Observational prospective
cohort  study
1  181 2  2.7 ± 2.5 No PEG-IFN 2a/b + RBV
2 131
3  78
Grasso 200931 Observational
prospective cohort
study
1  90 2 2.6 ± 2.1 No PEG-IFN 2b + RBV
Miyaaki 200932 Observational prospective
cohort  study
1  39 2  1.9 ± 0.87 No PEG-IFN 2b + RBV
2 12
Mizuta 201033 Observational
prospective cohort
study
1  51 2 1.92 Yes PEG-IFN 2b + RBV
Petta 200926 Observational
prospective cohort
study
1  83 2.7 2.73 ± 1.69 No PEG-IFN 2a + RBV
Poustchi 200816 Observational
prospective cohort
study
2/3  82 2 NA Yes IFN + RBV or PEG-IFN 2b + RBV
Romero-Gomez 200515 Observational
prospective cohort
study
1  113 2 3.01 ± 2.67 Yes PEG-IFN 2a/b + RBV
HOMA, homeostasis model of assessment; SVR, sustained virologic response; NA, non-available; PEG-IFN, peginterferon; RBV, ribavirin.
Data calculated using available information.
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Medine/Pubmed
all years
84 citations
Embase
all years
247 citations
The cochrane library
all years
0 citations
LILACS
all years
4 citations
Articles retrieves from
other sources
3 citations
302 non-duplicate
Citations
screened
Inclusion/Exclusion
criteria applied
54 articles retrieved
Inclusion/Exclusion
criteria applied
13 articles included
41 articles excluded
after full text screen
248 articles excluded
after title/Abstract screen
 of sFig. 1 – Fluxogram
in two studies that deﬁned it as HOMA-IR > 2.5,19,25 one that
considered HOMA-IR > 2.726 and another one that considered
HOMA-IR > 3.21 HOMA-IR and SVR showed statistically sig-
niﬁcant  association in eight studies and, according to the
genotypic  classiﬁcation of HCV, seven studies demonstrated
positive association for the genotype 1 group and three stud-
ies  for the genotypes 2 and 3. The other ﬁve studies did not
ﬁnd  a signiﬁcant association between HOMA-IR and SVR.
Meta-analysis  of  the  studies  that  evaluate  the  SVR  rates
in subjects  with  HCV  with  and  without  IR  deﬁned  by  a
cut-off  value  of  HOMA-IR
Thirteen selected studies, involving 2238 subjects, were
included in the meta-analysis (Table 1). According to the
analysis  including all selected studies, the SVR rates were
signiﬁcantly lower in subjects with IR, when compared to
those  without IR, regardless of the genotype, using the random
effects  model by the Dersimonian and Laird’s method (OR:
2.43;  95% CI: 1.77–3.35) (Fig. 2). Results remained unchanged
even when studies that used for the deﬁnition of IR a HOMA-
IR  > 2.5 or >2.7 or 3 were  excluded from the analysis (OR: 2.54;
95%  CI: 1.67–3.87) (Fig. 3).
To evaluate SVR rates in subjects with or without IR consid-
ering  speciﬁc genotypes, 12 studies were included involving
2156  subjects with HCV G1, among which ﬁve studies also
included  subjects with other genotypes. Nevertheless, for the
analysis,  only the speciﬁc results for HCV G1 were  consid-tudies selection.
ered. For the analysis of genotypes 2 and 3, six studies were
included  involving 552 subjects. Only results that reported
data  for genotypes 2 and 3 were added to the analysis.
The analysis demonstrated a negative and statistically
signiﬁcant association between the HOMA-IR index and
SVR  rates regardless of HCV genotypes: G1 (OR: 2.23; 95%
CI:  1.59–3.13) and G2/G3 (OR: 4.45; 95% CI: 1.59–12.49)
(Figs. 4 and 5). For each genotypic group (HCV G1 and HCV
G2/G3),  the impact of IR on SVR rates was  maintained, even
after  the exclusion of the studies with HOMA-IR index cut-off
different  from 2. (Data not shown – refer to supplementary
data.)
Discussion
This meta-analysis aimed to evaluate the impact of the IR
on  the response to antiviral treatment with IFN-RBV or PEG-
IFN  + RBV in subjects infected by HCV, taking into account
the  genotypic group G1 versus G2/G3. Thirteen studies were
included  involving 2238 infected subjects. The results demon-
strated  a statistically signiﬁcant association between IR and
lower  SVR rates, regardless of the genotypic group evaluated,
but  was more  evident on G2/G3: OR: 2.23; 95% CI: 1.59–3.13 and
OR:  4.45; 95% CI: 1.59–12.49, respectively for HCV G1 and G2/G3.Among  the selected studies for the meta-analysis, a differ-
ence  in the cut-offs used for IR deﬁnition using the HOMA-IR
index  was  noted. To minimize this limitation, sub-analysis
that excluded the studies that did not use 2 as a cut-off value
b r a z j i n f e c t d i s . 2 0 1 3;1 7(5):555–563  559
NOTE: Weights are from rando m effects analysis
Overall   (I-squ ared = 49.6%, p = 0.022 )
Chu 2008
Dai 2009
Fatto vich 201 0
Petta  2009
Miyaaki 2009
ID
Eslam 2012
Mizuta 2010
Romero-Gomez 200 5
Poustc h 2008
Conjeevaram 2007
Grasso 2009
Bortoletto  2010
Study
Akuta 2009
2.43 (1.77,  3.35)
10.64 (3.06,  36.95)
2.08 (1.20,  3.59)
1.39 (0.92,  2.09)
1.56 (0.63,  3.87)
2.74 (0.87,  8.62)
OR (95%  CI)
3.32 (1.50,  7.37)
5.98 (1.76,  20.32 )
3.13 (1.42,  6.88)
8.77 (1.87,  41.18 )
1.69 (1.11,  2.58)
1.58 (0.58,  4.29)
5.03 (1.50,  16.82 )
1.22 (0.43,  3.44)
100.00
4.81
11.78
13.86
7.31
5.43
Weight
8.46
4.94
8.56
3.44
13.67
6.50
5.03
%
6.21
1.0243  41.2
Heterogeneity Q = 23.79 (d.f. = 12) p = 0.022; I² = 49.6%; t² = 0.15; Test of OR = 1: p = 0. 000
Fig. 2 – Odds-ratio for the association between IR and SVR. Global analysis, according to the cut-off deﬁnition of the
HOMA-IR index used in each study.
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Fig. 3 – Odd-ratio for the association between IR and SVR. Analysis including only studies with HOMA-IR index cut-off > 2.
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HOMA-IR index cut-off used in each study.
was  performed and the results association between IR and SVR
remained unchanged for both genotypic groups (Figs. 6 and 7).
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The multicentric study Virahep-C also evaluated how much
IR  interferes with SVR.29 This study was  designed to evalu-
ate  the rates and predictors of SVR among Afro-American and
Caucasian  subjects infected by the HCV G1 under treatment
with  a combination of PEG-IFN + RBV. The HOMA-IR index
value  correlated signiﬁcantly with SVR rates (highest SVR rates
were associated with lowest HOMA-IR index value). In addi-
tion,  the HOMA-IR value decreased during therapy between
responders and non-responders, but this reduction was only
statistically  signiﬁcant among those who  achieved SVR. Chu
and  collaborators18 reported that IR played a decisive role on
SVR  in the treatment with PEG-IFN + RBV in Chinese subjects
infected  with HCV G1. Other studies support the data previ-
ously  reported for G1.19,21,30–33
Currently, interest in the study of genotypes 2 and 3
has  increased and two meta-analyses were  conducted to
demonstrate the relevance of IR in these cases. However, no
comparisons  versus genotype 1 were performed.34,35 In 2011,
Eslam  and collaborators published a meta-analysis aiming
to  evaluate the impact of IR on SVR in hepatitis C, but all
genotypes were studied in this analysis (1, 2, 3 and 4), with
no  distinction among them.34 The study concluded that the
increase  in the HOMA-IR index was  associated with lower
therapeutic response in subjects infected by HCV.
A  study published in 2008 by Poustchi and collaborators16
demonstrated that IR was  an independent predictor of lower
SVR  in subjects infected by genotypes 2 or 3 (OR for no-
response with HOMA-IR > 2 = 6.5; 95% CI: 1.3–31.9; p = 0.02).
Another  study in 62 subjects with different HCV genotypes (G1,
G2 and G3) has demonstrated that SVR was  reduced in patients
with  HOMA-IR > 3, but this difference was  not sustained when
analyzed  for each genotype individually, due to the limited
number  of subjects in each subgroup.21 However, Eslam30 with
the  purpose to investigate the effect of IR on SVR in 263 sub-
jects  with chronic hepatitis C, demonstrated that SVR rate
was  signiﬁcantly reduced among patients with HOMA-IR ≥ 2
for each genotype analyzed (G1, G3, and G4). This difference
was  maintained even when different cut-off values of HOMA-
IR  were  used to deﬁne IR (>3 and >4). As such, the presence of
IR,  measured by the HOMA-IR index, presents prognostic value
for standard therapy (PEG-IFN + RBV) also in patients with G2
or  G3. This therapy tends to remain the standard treatment
for  these genotypes over the next years in Brazil.
Despite these results, the SVR variation according to
HOMA-IR values remains a controversial issue, as some
studies  do not conﬁrm that IR can play an important role
in  SVR.20,25,26,31 Fattovich et al.20 reported an association
between HOMA-IR and rapid virologic response (RVR), but it
was not predictive of SVR, in the entire cohort and also in
HCV  genotypes subgroups. In the same way,  two other studies
evaluating  the response to therapy in subjects infected by G1
only  reported association with RVR and IR, but did not ﬁnd any
signiﬁcant  association with SVR.26,31 Dai and Thompson sug-
gested  in their studies that viral eradication was  associated
with  IR in patients infected by G1, but such association was
not  seen in patients infected by G2 or G3.19,22This meta-analysis included the studies previously men-
tioned,  initially assessing presence or absence of IR, regardless
of  the cut-off value used in HOMA-IR and, subsequently,
including only those with cut-off value ≥2. On both it was  clear 1 3;1  7(5):555–563
that the presence of IR was  associated with reduced SVR rates
in  patients infected by HCV G1 and G2/G3, and that HOMA-IR
index  can be used as a predictive factor for SVR in patients with
G1,  as well as on those with G2/G3. This an important point
once  there is no consensus regarding the HOMA-IR value lim-
its  that deﬁnes IR because values of 2; 2.5; 2.7 and 3 have been
used.  Besides, further studies to assess SVR in patients with G2
and  G3 should be conducted to strengthen pre-existing data
on  its association with IR.
The discrepancy among the results in the selected studies
must  take into consideration that the interaction between IR
and SVR also depends on other factors that need to be consid-
ered  in the data interpretation. Besides the cut-off value used
in  the deﬁnition of IR, basal characteristics of the study cohort
and  the technical adequacy in collecting and measuring the
serum  insulin sample are of paramount importance. In this
last  case, different assays can present signiﬁcant differences
in  determining serum insulin levels.36 On the other hand, both
fasting  glucose levels and serum insulin levels are potentially
modiﬁable factors on a short period of time, through lifestyle
changes  (diet and exercise) as well as a result of medication.
Thus, patients with chronic hepatitis C that are candi-
dates to antiviral therapy with PEG-IFN + RBV must be checked
for  IR before being started on treatment since HOMA-IR
index presents a prognostic value for SVR in these patients,
regardless of their genotypes. Although controversial, the
modulation  of insulin signaling and improvement in IR and
serum  glucose control should be attempted aiming at a better
therapeutic  response.37
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